Contineum Therapeutics (CTNM) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.40

Estimate

-$0.45

Surprise

+10.8%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Contineum Therapeutics (CTNM) reported a narrower loss than forecast — adjusted EPS of -$0.40 against the -$0.45 estimate (a 10.8% beat on a still-unprofitable quarter).

TrendMatrix currently rates CTNM Hold at 5.4/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +10.8% surprise compares with a +3.2% four-quarter average. Next scheduled report: 2026-10-29.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$9.69

Price target

$19.26

Stop

$9.01

Upside to target

+98.8%

Reward-to-risk

6.6:1

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$344.2M

P/E (fwd)

-4.7

52-week range

$6.72–$17.79

Off 52-week high

45.5%

RSI (14)

31

Volume vs avg

0.02×

Score today

5.4/10